This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deak, T. Articles by Gold, P. W. Search for Related Content PubMed PubMed Citation Articles by Deak, T. Articles by Gold, P. W.

The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress¹

Department of Psychology (T.D., K.T.N., A.L.E., L.R.W., R.L.S., S.F.M.), University of Colorado, Boulder, Colorado 80309-0345; Clinical Neuroendocrinology Branch (J.L., M.-L.W., P.W.G.), National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1284; and Developmental Neuroendocrinology Branch (G.P.C., E.W.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1284

Address all correspondence and requests for reprints to: Terrence Deak, Campus Box 345, Department of Psychology, University of Colorado, Boulder, Colorado 80309-0345. E-mail: tdeak{at}clipr.colorado.edu

The nonpeptide CRH antagonist antalarmin has been shown to block both behavioral and endocrine responses to CRH. However, it’s potential activity in blunting behavioral and endocrine sequelae of stressor exposure has not been assessed. Because antagonism of central CRH by -helical CRH attenuates conditioned fear responses, we sought to test antalarmin in this regard. In addition, it remains unclear as to whether this is a result of receptor blockade during conditioning or during testing. Thus, we explored whether CRH mediates the induction or expression of conditioned fear (freezing in a context previously associated with 2 footshocks; 1.0 mA, 5 sec each). Furthermore, because rats previously exposed to inescapable shock (IS; 100 shocks, 1.6 mA, 5 sec each), demonstrate enhanced fear conditioning, we investigated whether this effect would be blocked by antalarmin. Antalarmin (20 mg/kg·2 ml ip) impaired both the induction and expression of conditioned fear. In addition, antalarmin blocked the enhancement of fear conditioning produced by prior exposure to IS. Despite the marked behavioral effects observed in antalarmin-treated rats, antalarmin had no effect on IS-induced rises in ACTH or corticosterone. However, antalarmin did block the ACTH response produced by exposure to 2 footshocks.

This article has been cited by other articles:

				C. Doyon, P. Samson, J. Lalonde, and D. Richard Effects of the CRF1 receptor antagonist SSR125543 on energy balance and food deprivation-induced neuronal activation in obese Zucker rats J. Endocrinol., April 1, 2007; 193(1): 11 - 19. [Abstract] [Full Text] [PDF]

				S. Ma, M. J. Shipston, D. Morilak, and J. A. Russell Reduced Hypothalamic Vasopressin Secretion Underlies Attenuated Adrenocorticotropin Stress Responses in Pregnant Rats Endocrinology, March 1, 2005; 146(3): 1626 - 1637. [Abstract] [Full Text] [PDF]

				A. R. Ayala, J. Pushkas, J. D. Higley, D. Ronsaville, P. W. Gold, G. P. Chrousos, K. Pacak, K. A. Calis, M. Gerald, S. Lindell, et al. Behavioral, Adrenal, and Sympathetic Responses to Long-Term Administration of an Oral Corticotropin-Releasing Hormone Receptor Antagonist in a Primate Stress Paradigm J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5729 - 5737. [Abstract] [Full Text] [PDF]

				E. Charmandari, D. P. Merke, P. J. Negro, M. F. Keil, P. E. Martinez, A. Haim, P. W. Gold, and G. P. Chrousos Endocrinologic and Psychologic Evaluation of 21-Hydroxylase Deficiency Carriers and Matched Normal Subjects: Evidence for Physical and/or Psychologic Vulnerability to Stress J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2228 - 2236. [Abstract] [Full Text] [PDF]

				A. Chen, J. Vaughan, and W. W. Vale Glucocorticoids Regulate the Expression of the Mouse Urocortin II Gene: A Putative Connection between the Corticotropin-Releasing Factor Receptor Pathways Mol. Endocrinol., August 1, 2003; 17(8): 1622 - 1639. [Abstract] [Full Text] [PDF]

				S. E. Hammack, M. J. Schmid, M. L. LoPresti, A. Der-Avakian, M. A. Pellymounter, A. C. Foster, L. R. Watkins, and S. F. Maier Corticotropin Releasing Hormone Type 2 Receptors in the Dorsal Raphe Nucleus Mediate the Behavioral Consequences of Uncontrollable Stress J. Neurosci., February 1, 2003; 23(3): 1019 - 1025. [Abstract] [Full Text] [PDF]

				P. Esposito, N. Chandler, K. Kandere, S. Basu, S. Jacobson, R. Connolly, D. Tutor, and T. C. Theoharides Corticotropin-Releasing Hormone and Brain Mast Cells Regulate Blood-Brain-Barrier Permeability Induced by Acute Stress J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1061 - 1066. [Abstract] [Full Text] [PDF]

				S. Agelaki, C. Tsatsanis, A. Gravanis, and A. N. Margioris Corticotropin-Releasing Hormone Augments Proinflammatory Cytokine Production from Macrophages In Vitro and in Lipopolysaccharide-Induced Endotoxin Shock in Mice Infect. Immun., November 1, 2002; 70(11): 6068 - 6074. [Abstract] [Full Text] [PDF]

				M. A. Pelleymounter, M. Joppa, N. Ling, and A. C. Foster Pharmacological Evidence Supporting a Role for Central Corticotropin-Releasing Factor2 Receptors in Behavioral, but not Endocrine, Response to Environmental Stress J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 145 - 152. [Abstract] [Full Text] [PDF]

				D. Jezova and R. Duncko Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men J Psychopharmacol, May 1, 2002; 16(3): 235 - 240. [Abstract] [PDF]

				T. Blank, I. Nijholt, K. Eckart, and J. Spiess Priming of Long-Term Potentiation in Mouse Hippocampus by Corticotropin-Releasing Factor and Acute Stress: Implications for Hippocampus-Dependent Learning J. Neurosci., May 1, 2002; 22(9): 3788 - 3794. [Abstract] [Full Text] [PDF]

				D. P. Merke, S. R. Bornstein, N. A. Avila, and G. P. Chrousos Future Directions in the Study and Management of Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Ann Intern Med, February 19, 2002; 136(4): 320 - 334. [Abstract] [Full Text] [PDF]

				S. E. Hammack, K. J. Richey, M. J. Schmid, M. L. LoPresti, L. R. Watkins, and S. F. Maier The Role of Corticotropin-Releasing Hormone in the Dorsal Raphe Nucleus in Mediating the Behavioral Consequences of Uncontrollable Stress J. Neurosci., February 1, 2002; 22(3): 1020 - 1026. [Abstract] [Full Text] [PDF]

				K. Erickson, P. Thorsen, G. Chrousos, D. E. Grigoriadis, O. Khongsaly, J. McGregor, and J. Schulkin Preterm Birth: Associated Neuroendocrine, Medical, and Behavioral Risk Factors J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2544 - 2552. [Abstract] [Full Text] [PDF]

				L. Arborelius, K. H. Skelton, K. V. Thrivikraman, P. M. Plotsky, D. W. Schulz, and M. J. Owens Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 588 - 597. [Abstract] [Full Text]

				K. E. Habib, K. P. Weld, K. C. Rice, J. Pushkas, M. Champoux, S. Listwak, E. L. Webster, A. J. Atkinson, J. Schulkin, C. Contoreggi, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates PNAS, May 23, 2000; 97(11): 6079 - 6084. [Abstract] [Full Text] [PDF]

				S. C. Weninger, A. J. Dunn, L. J. Muglia, P. Dikkes, K. A. Miczek, A. H. Swiergiel, C. W. Berridge, and J. A. Majzoub Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH PNAS, July 6, 1999; 96(14): 8283 - 8288. [Abstract] [Full Text] [PDF]